CARDIFF ONCOLOGY DATA CONTINUES TO DEMONSTRATE EFFICACY, DURABILITY AND SAFETY OF ONVANSERTIB IN PATIENTS WITH DIFFICULT-TO-TREAT RELAPSED/REFRACTORY AML
San Diego, 15.06.2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate...
NICE APPROVES NEW RARE LUNG CANCER TREATMENT FROM ROCHE
15.06.2020 By Emma Morriss, Pharmafield The National Institute for Health and Care Excellence (NICE) has approved a new rare lung cancer treatment. NICE has published its decision to grant a positive final appraisal document (FAD) for the use of Roche’s Rozlytrek®▼...
CARDIFF ONCOLOGY ANNOUNCES EXPANDED ACCESS PROGRAM FOR ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER AS FOLLOW-ON TO FAST TRACK DESIGNATION
San Diego, 09.06.2020 For the full press release: https://cardiffoncology.investorroom.com/2020-06-09-Cardiff-Oncology-Announces-Expanded-Access-Program-for-Onvansertib-in-KRAS-Mutated-Metastatic-Colorectal-Cancer-as-Follow-On-to-Fast-Track-Designation
CHMP RECOMMENDS EU APPROVAL OF ROCHE’S ROZLYTREK® (ENTRECTINIB) FOR PEOPLE WITH NTRK FUSION-POSITIVE SOLID TUMOURS AND FOR PEOPLE WITH ROS1-POSITIVE, ADVANCED NON-SMALL CELL LUNG CANCER
Basel, 29.05.2020 Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under conditional marketing authorisation for...
CARDIFF ONCOLOGY DATA CONTINUES TO DEMONSTRATE EFFICACY OF ONVANSERTIB IN PATIENTS WITH KRAS-MUTATED METASTATIC COLORECTAL CANCER PRESENTED AT ASCO
San Diego, 29.05.2020 We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) : Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the...
CARDIFF ONCOLOGY ANNOUNCES FAST TRACK DESIGNATION GRANTED BY THE FDA TO ONVANSERTIB FOR SECOND-LINE TREATMENT OF KRAS-MUTATED COLORECTAL CANCER
San Diego, 28.05.2020 We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) : Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the...
PHASE 2, THE BATTLE CONTINUES AND NMS GROUP WILL KEEP PROTECTING OUR NERVIANO COMMUNITY
Nerviano, 19.05.2020 Today, the NMS Group has kept its promise and donated another 5,000 masks to the Nerviano community. “As the lockdown eventually eases and we all can enjoy a bit more freedom to move, here in the NMS Group campus that we think and act according to...
CARDIFF ONCOLOGY ENTERS AGREEMENT WITH POC CAPITAL TO FUND PHASE 2 CLINICAL TRIAL OF ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC)
San Diego, 13.05.2020 We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) : Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the...
ONVANSERTIB TRIAL IN KRAS-MUTATED COLORECTAL CANCER DEMONSTRATES CONSISTENT TUMOR REGRESSION ACROSS KRAS MUTATION SUBTYPES AND DURABLE RESPONSE
San Diego, 28.04.2020 We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) : Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest...
HEALTH CANADA APPROVES ROZLYTREK® (ENTRECTINIB) FOR NTRK GENE FUSION-POSITIVE SOLID TUMOURS IN LOCALLY ADVANCED OR METASTATIC PATIENTS(1)
Canada, 28.04.2020 MISSISSAUGA, ON, April 28, 2020 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on February 10, 2020, Health Canada, under the Notice of Compliance with Conditions (NOC/c) policy, approved Rozlytrek® (entrectinib) for...
Our Archive
Welcome and Check out our new motion picture!